Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K.
- 31 January 2001
- journal article
- Published by Elsevier in Respiratory Medicine
- Vol. 95 (1) , 83-89
- https://doi.org/10.1053/rmed.2000.1006
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- How should cost data in pragmatic randomised trials be analysed?BMJ, 2000
- Montelukast Added to Inhaled Beclomethasone in Treatment of AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 1999
- Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstrictionJournal of Allergy and Clinical Immunology, 1999
- Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patientsBMJ, 1999
- Leukotriene modifiers as novel therapeutics in asthmaClinical and Experimental Allergy, 1998
- Montelukast, a Leukotriene-Receptor Antagonist, for the Treatment of Mild Asthma and Exercise-Induced BronchoconstrictionNew England Journal of Medicine, 1998
- Montelukast, a Once-Daily Leukotriene Receptor Antagonist, in the Treatment of Chronic AsthmaA Multicenter, Randomized, Double-blind TrialArchives of internal medicine (1960), 1998
- The costs of asthmaEuropean Respiratory Journal, 1996
- Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterolRespiratory Medicine, 1994
- Impact of an interest in asthma on prescribing costs in general practice.Quality and Safety in Health Care, 1992